New hope for rare ovarian cancer? belzutifan trial opens

NCT ID NCT06677190

First seen Nov 05, 2025 · Last updated May 21, 2026 · Updated 31 times

Summary

This study tests whether the drug belzutifan can shrink or slow the growth of clear cell cancers of the ovary, uterus, cervix, vagina, or vulva that have come back or not gone away. About 32 adults will receive belzutifan pills and be monitored for tumor response and side effects. The goal is to see if this targeted therapy offers a new treatment option for these hard-to-treat cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana-Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.